AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01760226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be given by mouth at 60mg/m2/dose (based on height and weight) twice a day on days 1-5 of each cycle.
Study NCT01134978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Order
Description: Blocked order - predictable~Random order - unpredictable
Study NCT01152086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mountain hiking in the Austrian and Bavarian Alps
Description: Regularly supervised physical exercise training program.~Duration over all: 9 weeks; Frequency: 2 times per week; Duration one training-unit: 3 hours;~Program:~* Endurance training (performed within 70-85% of the maximum heart rate)~* Short exercises before hiking (Mobilisation, Body and nature perception, ca. 5 min)~* Stretching after hiking (ca. 5 min)~* Short break at half-time (ca. 15 min)
Study NCT00865774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantity Frequency Model
Description: The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.
Study NCT00865774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targets Subjective Drunkenness
Description: Explores factors leading to drunkenness and alternative coping strategies for healthier function.
Study NCT03021408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRT + Treadmill
Description: PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill training twice per day, 5 times a week, for 4 weeks.
Study NCT03021408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRT + Treadmill Plus
Description: PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill-plus training (with visual and auditory cues) twice per day, 5 times a week, for 4 weeks.
Study NCT03021408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRT + Virtual Reality
Description: PD patients will undergo a 4-week MIRT. All patients in the MIRT+Virtual Reality (VR) group will undergo 10-minutes VR training with enhanced perceptions (visual, auditory, and haptic inputs), twice per day, 5 times a week, for 4 weeks.
Study NCT03381846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MOHS micrographic surgery
Description: Mohs surgery is a precise surgical technique used to treat skin cancer. Thin layers of cancer-containing skin are progressively removed and examined microscopically until only cancer-free tissue remains.
Study NCT03381846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide local excision
Description: A surgical technique in which the skin cancer is excised along with 2-3 cm of clinically normal appearing surrounding tissue.
Study NCT01561365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ottawa ankle rules
Description: Ottawa ankle rules implementation
Study NCT02313181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Limited Formula
Description: 10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
Study NCT02313181 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Continue exclusive breastfeeding unless otherwise directed by a health care provider
Study NCT02016560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Study NCT02016560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Study NCT02016560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain
Study NCT02744235 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Polysomnography Data
Study NCT02744235 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Jawbone UP®
Study NCT02744235 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fitbit Charge ®
Study NCT04047498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternating DBS
Description: Constant DBS will be changed to DBS that is up- and downmodulated alternating between the left and right stimulation side.
Study NCT03853265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated dental office visit
Description: An immersive first-person point of view (POV) video simulation of the dental office in the three-dimensional environment (using a virtual reality headset) which allows participant to look around the room as they move down the hallways which is to be watched/experienced by the participant as often as possible between the initial visit and the follow up visit
Study NCT02674152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Study NCT00208611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 Supplementation
Description: 1000 micrograms daily
Study NCT04171778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole food, plant-based diet
Description: The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.
Study NCT04171778 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: whole food, plant-based diet
Description: The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.
Study NCT06001424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: Frenkel's exercises for lower limb, Proprioceptive neuromuscular facilitation for upper limb in the form of rhythmic stabilization
Study NCT06001424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Frenkel's exercises for lower limb, Proprioceptive neuromuscular facilitation for upper limb in the form of rhythmic stabilization
Study NCT06001424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: life kinetic exercises
Description: A multimodal training that combines coordinative, cognitive and visual tasks.
Study NCT00720837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visualase® Thermal Therapy System
Description: An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
Study NCT02590653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Lipid-lowering therapy
Study NCT02590653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Lipid-lowering therapy
Study NCT01760226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF will be given at 5 mcg/kg/day during each cycle, starting on day 6, until the patient's ANC (absolute neutrophil count) is greater than 5000/mcL past nadir.
Study NCT01335867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Vigabatrin escalated to 3 grams daily for 8 weeks
Study NCT01335867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills
Study NCT01619059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
Study NCT01619059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
Study NCT04149158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04149158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sinetrol® Xpur
Study NCT01222091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.
Study NCT01222091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.
Study NCT01222091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Match Propranolol
Study NCT01222091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Match Propranolol
Study NCT01222091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
Study NCT01222091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
Study NCT03093207 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Open flap debridement
Description: Open flap debridement will be performed to decontaminate root surface
Study NCT03093207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement
Description: Open flap debridement will be performed to decontaminate root surface
Study NCT03093207 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills over a period of 180 days
Study NCT03093207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids
Description: 3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
Study NCT03093207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 100 mg of aspirin daily supplementation over a period of 180 days
Study NCT04293510 — intervention group
Intervention type: PROCEDURE
Intervention: renal biopsy and blood sampling
Description: renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3
Study NCT01814878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl/Acetaminophen ER
Description: 2 tablets of ER (tramadol HCl \[75 mg\]/acetaminophen \[650 mg\]) will be administered at 0, 12, 24 and 36 hours
Study NCT01814878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol HCl/Acetaminophen IR
Description: 2 tablets of IR (tramadol HCl \[37.5 mg\]/acetaminophen \[325 mg\]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
Study NCT01029990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone arm
Description: Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.
Study NCT01029990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-test arm
Description: Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
Study NCT04660825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A resistance band exercise programme
Description: A resistance band based exercise programme lasting six months
Study NCT04660825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Maintained usual physical activity
Study NCT01116024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATS 3f Enable Aortic Bioprosthesis Model 6000
Description: Replacement Aortic Heart Valve
Study NCT02660671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email outreach
Description: Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
Study NCT02660671 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Email outreach
Description: Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
Study NCT02660671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active choice
Description: S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
Study NCT02660671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
Study NCT02872896 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthopedic, urologic or general surgery
Description: Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
Study NCT02872896 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Orthopedic, urologic or general surgery
Description: Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
Study NCT03341078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibudilast
Description: Ibudilast capsules will be orally ingested twice daily for 6 weeks.
Study NCT03341078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo capsules will be orally ingested twice daily for 6 weeks.
Study NCT02074345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-816
Description: TAK-816 intramuscular injection
Study NCT04224636 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection, Bevacizumab Injection
Description: Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE
Study NCT01938924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GekoTM
Description: electrical neuromuscular stimulation
Study NCT00519376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M
Description: drug
Study NCT00519376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444H
Description: drug
Study NCT00519376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT04445922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test-anastrozole tablet (Salutas Pharma GmbH)
Description: Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
Study NCT04445922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference-anastrozole tablet
Description: Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
Study NCT01991028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled OligoG CF-5/20 DPI
Description: Inhalation with dry powder by Mia Monodose Inhaler
Study NCT01991028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiolabelled OligoG CF-5/20 6% Solution
Description: Inhalation with aerosolised solution by nebuliser
Study NCT01617174 — intervention group
Intervention type: BEHAVIORAL
Intervention: Webcore telephone survey system
Description: Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.
Study NCT01991067 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TBE virus vaccine
Description: TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
Study NCT01029574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Platelet rich plasma
Description: Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
Study NCT01029574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
Study NCT04062175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cephalosporin
Description: 72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision
Study NCT04062175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Tablets
Description: 72 women will receive combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery +cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
Study NCT03555201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: protocol of soft tissues techniques
Study NCT03555201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular treatment control.
Description: Regular treatment control.
Study NCT01920789 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (\<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.
Study NCT01920789 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally fractionated radiotherapy
Description: Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.
Study NCT04252456 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aflibercept, 5fluorouracil, Folinic Acid andIrinotecan
Description: All patients will receive aflibercept in combination with FOLFIRI according to the Italian label
Study NCT01618994 — intervention group
Intervention type: PROCEDURE
Intervention: Performing robotic supracervical hysterectomy
Description: All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy
Study NCT02257944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Brief hospital-based intervention, rooted in motivational interviewing
Study NCT06505070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreational Games
Description: 40 individuals in the intervention group were introduced to 15 games. Researchers conducted these sessions and provided participants with instructions and rules for the games. Then, they were asked to rate the games from 1 to 10. In this form, the elderly individuals evaluated the games by determining the minimum 1 and maximum 10 points according to their interest and willingness to play. Thus, it was ensured that individuals freely choose the games they want to play. As a result, bingo, matching pairs, word challenges and hot-cold games, which received the highest scores from the participants, were selected to be played.
Study NCT02960490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: subcutaneous administration
Study NCT02257944 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: treatment as usual
Study NCT03062683 — intervention group
Intervention type: OTHER
Intervention: Lactate, prolactin and creatine kinase conc.
Description: Lactate, prolactin and creatine kinase conc. in blood samples were measured
Study NCT00789139 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ICM Implantation
Description: Sub cutaneous implantation of the ICM
Study NCT02079181 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 d-FMAU
Description: Given IV
Study NCT02079181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo fluorine F 18 d-FMAU PET/CT scan
Study NCT02960490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneous administration